Xceleron and Covance have entered a co-promotional agreement in which both companies will make available their drug development services to customers. The two companies will carry out joint projects on behalf of sponsors and further the development of new applications. Xceleron chief executive officer, professor Colin Garner, said, “This is a strategically important deal for Xceleron. It demonstrates how quickly our technology has moved from being seen as novel and at the edges of dru...